CN Mobile Logo


Hematologic Malignancies

Melanoma Risk Increased in CLL/SLL Patients

Results of a new study have indicated that the risk of developing melanoma may be almost doubled among survivors of chronic lymphocytic leukemia/small lymphocytic lymphoma who were treated with certain chemotherapeutic agents or who had specific immune-related medical conditions.

Hematologic Malignancies

Allogeneic HSCT may be the best treatment option in older patients with acute myeloid leukemia who obtain first complete remission after induction chemotherapy.

Patients who are in complete remission from diffuse large B-cell lymphoma may not need to undergo routine imaging follow-up, a new study showed.

A new risk assessment score more accurately reflects the probability of dying from chronic myeloid leukemia than do existing scoring systems.

Treatment with intermittent imatinib is feasible among elderly CML patients who are stable responders to the drug, according to a new study.

GM-CSF was associated with lower transplantation-related and cumulative mortality among patients undergoing allogeneic hematopoietic stem cell transplantation.

Data taken from EUROCARE showed large variations in survival rates from several hematologic malignancies across European countries, with lower survival in Eastern Europe and higher survival in Northern and Central Europe.

The antibody-drug conjugate brentuximab vedotin is effective as a frontline therapy for Hodgkin lymphoma patients over age 60 who are unfit for chemotherapy.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.